01—Abstract
Summary
Summary of the 10-K filed February 18, 2011. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2010 annual report, highlighting its strategic focus on RNA interference (RNAi) therapeutics.
The company is advancing its 'Alnylam 5x15' strategy, aiming to bring five RNAi therapeutic programs into advanced clinical development by the end of 2015. Alnylam is currently developing three core programs: ALN-TTR for transthyretin-mediated amyloidosis (ATTR), ALN-PCS for severe hypercholesterolemia, and ALN-HPN for refractory anemia. Financially, Alnylam reported net revenues from research collaborators of $100.0 milliona for 2010, with total operating expenses of $144.1 million, resulting in a net loss of $43.5 million.
The company ended 2010 with $349.9 millionb in cash, cash equivalents, and marketable securities, indicating a strong cash position to fund ongoing research and development activities. Alnylam also emphasized its robust intellectual property portfolio and a strong base of strategic alliances with major pharmaceutical companies, which provide significant financial support and operational capabilities.
02—Key points
Key Highlights
- Alnylam is advancing its 'Alnylam 5x15' strategy, targeting five RNAi therapeutic programs for advanced clinical development by 2015.
- Key development programs include ALN-TTR (ATTR), ALN-PCS (severe hypercholesterolemia), and ALN-HPN (refractory anemia).
- Net revenues from research collaborators reached $100.0 million in 2010.
- The company reported a net loss of $43.5 million for 2010.
- Alnylam maintained a strong cash position with $349.9 million in cash, cash equivalents, and marketable securities at year-end 2010.
- A significant corporate restructuring in September 2010 reduced the workforce by approximately 25% to focus resources on promising programs and reduce costs.
- The company highlighted its extensive intellectual property portfolio and numerous strategic alliances with leading pharmaceutical and biotechnology companies.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 18, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $100.04M$100.53M | −0.5% |
| R&D Expenses | $106.38M$108.73M | −2.2% |
| Operating Expenses | $144.11M$148.64M | −3.0% |
| Operating Income | -$44.07M-$48.11M | +8.4% |
| Net Income | -$43.52M-$47.59M | +8.6% |
| EPS (Basic) | $-1.04$-1.14 | +8.8% |
| Shares Outstanding (Basic) | 42.04M— | — |
05—Questions
Frequently Asked Questions
What is Alnylam's core business strategy for developing new therapeutics?
Alnylam's core strategy, termed 'Alnylam 5x15,' focuses on developing innovative RNAi therapeutics for genetically defined diseases. The goal is to advance five such programs into advanced clinical development by the end of 2015, with each program expected to target a genetically defined disease, address a significant unmet medical need, leverage Alnylam's delivery platform, allow for early biomarker monitoring, and have clear clinical endpoints for regulatory approval.
What are Alnylam's most advanced drug development programs?
As of the February 2011 filing, Alnylam's most advanced core development programs were ALN-TTR for transthyretin-mediated amyloidosis (ATTR), ALN-PCS for severe hypercholesterolemia, and ALN-HPN for refractory anemia. They also had partner-based programs in clinical or pre-clinical development, including ALN-RSV01 for RSV infection, ALN-VSP for liver cancers, and ALN-HTT for Huntington's disease.
How is Alnylam generating revenue at this stage of development?
Alnylam's revenue is primarily generated through strategic alliances and collaborations with pharmaceutical and biotechnology companies. These collaborations provide upfront payments, research funding, milestone payments, and potential royalties. For the year ended December 31, 2010, net revenues from these research collaborators totaled $100.0 million.
What are the key risks associated with Alnylam's RNAi technology?
Alnylam acknowledges that its RNAi therapeutic approach is unproven and faces significant risks. These include challenges in demonstrating the safety and efficacy of siRNAs as drugs, potential off-target effects, activation of the interferon response, and difficulties in achieving adequate stability and cellular uptake of siRNAs. The company also faces substantial competition from other RNAi developers and established drug classes like antisense technology.
06—Continue